Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 2CNS 2Breast 2Lymphoid 1

Conditions

Breast Neoplasms 2Breast Neoplasms, Male 1

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Antibodies, Monoclonal × Breast × Clear all
NCT01873833 2023-10-05

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

University of Southern California

Phase 2 Terminated
10 enrolled 16 charts
Breast

Breast Neoplasms

NCT03112590 2023-04-19

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
51 enrolled 13 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡